Title: EFFECTS OF EMPAGLIFLOZIN ON OVERALL HEART FAILURE BURDEN IN EMPA-REG OUTCOME
Abstract: Empagliflozin reduced adjudicated heart failure (hospitalisation (HHF) by 35%; and the composite of adjudicated HHF and cardiovascular (CV) death by 34%) in the EMPA-REG OUTCOME trial. Since the independent adjudication committee adheres to standardized definitions for assignment to specific outcomes, some investigator-reported HF events do not fulfil standardised adjudication criteria. We therefore attempted to further assess the impact of empagliflozin on the overall HF burden, analysing effects on a) investigator reported HF episodes, b) the combination of investigator reported HF episodes plus adjudicated HHF, and c) initiation of loop diuretics as a proxy for incident HF.
Publication Year: 2016
Publication Date: 2016-09-28
Language: en
Type: article
Indexed In: ['crossref']
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot